Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hashemi, Sayed
REZILIENT3, NCT05973773: (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)	Recruiting	3	272	Europe, Canada, Japan, US, RoW	TAS6417, Zipalertinib, CLN-081	Taiho Oncology, Inc.	Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation	07/26	08/26
AMAZE-lung, NCT05601973 / 2021-002337-42: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI	Recruiting	2	60	Europe	Amivantamab, Lazertinib, Zirabev	ETOP IBCSG Partners Foundation, Janssen Pharmaceuticals	Non Small Cell Lung Cancer	03/26	09/26
NCT05376891: Met Non Small Cell Cancer Registry (MOMENT)	Recruiting	N/A	700	Europe, Canada, US, RoW		EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Cancer	03/27	03/27